OrphoMed: OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

(marketscreener.com) --Analysis triggered after meeting enrollment milestone of 200 patients-- --Topline data anticipated second half of 2021-- https://www.marketscreener.com/news/latest/OrphoMed-Passes-First-Interim-Analysis-in-Phase-2-Study-of-Treatment-for-IBS-D-Patients--32277928/?utm_medium=RSS&utm_content=20210126